Clinical Trial Update: The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating highly selective androgen receptor–targeted therapy in men with biochemically relapsed hormone-sensitive prostate cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-03-11